Cite
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
MLA
Lübbert, Michael, et al. “10-Day Decitabine versus 3 + 7 Chemotherapy Followed by Allografting in Older Patients with Acute Myeloid Leukaemia: An Open-Label, Randomised, Controlled, Phase 3 Trial.” The Lancet Haematology, vol. 10, no. 11, Nov. 2023, pp. e879–89. EBSCOhost, https://doi.org/10.1016/S2352-3026(23)00273-9.
APA
Lübbert, M., Wijermans, P. W., Kicinski, M., Chantepie, S., Van der Velden, W. J. F. M., Noppeney, R., Griškevičius, L., Neubauer, A., Crysandt, M., Vrhovac, R., Luppi, M., Fuhrmann, S., Audisio, E., Candoni, A., Legrand, O., Foà, R., Gaidano, G., van Lammeren-Venema, D., Posthuma, E. F. M., … de Jonge-Peeters, S. D. (2023). 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology, 10(11), e879–e889. https://doi.org/10.1016/S2352-3026(23)00273-9
Chicago
Lübbert, Michael, Pierre W Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J F M Van der Velden, Richard Noppeney, Laimonas Griškevičius, et al. 2023. “10-Day Decitabine versus 3 + 7 Chemotherapy Followed by Allografting in Older Patients with Acute Myeloid Leukaemia: An Open-Label, Randomised, Controlled, Phase 3 Trial.” The Lancet Haematology 10 (11): e879–89. doi:10.1016/S2352-3026(23)00273-9.